Journal of Medicinal Chemistry p. 4401 - 4410 (2019)
Update date:2022-08-05
Topics:
Riggs, Jennifer R.
Elsner, Jan
Cashion, Dan
Robinson, Dale
Tehrani, Lida
Nagy, Mark
Fultz, Kimberly E.
Krishna Narla, Rama
Peng, Xiaohui
Tran, Tam
Kulkarni, Ashutosh
Bahmanyar, Sogole
Condroski, Kevin
Pagarigan, Barbra
Fenalti, Gustavo
Lebrun, Laurie
Leftheris, Katerina
Zhu, Dan
Boylan, John F.
Triple negative breast cancer (TNBC) is an aggressive disease with high relapse rates and few treatment options. Outlined in previous publications, we identified a series of potent, dual TTK/CLK2 inhibitors with strong efficacy in TNBC xenograft models. P
View MoreHangzhou Eastbiopharm Co.,Ltd.
Contact:+86-571-88931780
Address:Hangzhou,China
Shijiazhuang Sdyano Fine Chemical Co., Ltd
Contact:+86-311-89830448
Address:NO.48 Ta Nan Road,Yuhua District,Shijiazhuang,Hebei,China
Chengdu ZY Biochemical Technology Co., LTD
Contact:0086-28-88680086
Address:170 Qingpu Road, Shouan Town, Pujiang County
Shaanxi HuaTai Bio-fine chemical company Ltd
Contact:86-029-87862197
Address:No. 5, 3rd Floor, 29 Yanta North Road, Beilin Dist.
Synochem Ingredients Corp., Ltd.
Contact:+86-512-5636 2180
Address:Zhangjiagang Free Trade Zone
Doi:10.1021/ol503655a
(2015)Doi:10.3987/com-02-9607
(2003)Doi:10.1016/S0022-328X(00)83682-7
(1974)Doi:10.1248/cpb.22.2004
(1974)Doi:10.1021/jo00896a027
(1975)Doi:10.1021/ja01559a069
(1957)